[go: up one dir, main page]

MX2020002485A - Metodos de uso del dantroleno para tratar la exposicion a agente nervioso. - Google Patents

Metodos de uso del dantroleno para tratar la exposicion a agente nervioso.

Info

Publication number
MX2020002485A
MX2020002485A MX2020002485A MX2020002485A MX2020002485A MX 2020002485 A MX2020002485 A MX 2020002485A MX 2020002485 A MX2020002485 A MX 2020002485A MX 2020002485 A MX2020002485 A MX 2020002485A MX 2020002485 A MX2020002485 A MX 2020002485A
Authority
MX
Mexico
Prior art keywords
dantrolene
methods
nerve agent
agent exposure
treat nerve
Prior art date
Application number
MX2020002485A
Other languages
English (en)
Inventor
Adrian Hepner
Original Assignee
Eagle Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eagle Pharmaceuticals Inc filed Critical Eagle Pharmaceuticals Inc
Publication of MX2020002485A publication Critical patent/MX2020002485A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La divulgación está dirigida a métodos de tratamiento de sujetos expuestos a agentes nerviosos con dantroleno, o una sal farmacéuticamente aceptable del mismo.
MX2020002485A 2017-09-05 2018-09-05 Metodos de uso del dantroleno para tratar la exposicion a agente nervioso. MX2020002485A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762554049P 2017-09-05 2017-09-05
US201862674406P 2018-05-21 2018-05-21
PCT/US2018/049515 WO2019050923A1 (en) 2017-09-05 2018-09-05 METHODS OF USING DANTROLENE TO TREAT EXPOSURE TO A NEUROTOXIC AGENT

Publications (1)

Publication Number Publication Date
MX2020002485A true MX2020002485A (es) 2020-07-20

Family

ID=63708449

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020002485A MX2020002485A (es) 2017-09-05 2018-09-05 Metodos de uso del dantroleno para tratar la exposicion a agente nervioso.
MX2023012415A MX2023012415A (es) 2017-09-05 2020-03-04 Metodos de uso del dantroleno para tratar la exposicion a agente nervioso.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023012415A MX2023012415A (es) 2017-09-05 2020-03-04 Metodos de uso del dantroleno para tratar la exposicion a agente nervioso.

Country Status (16)

Country Link
US (2) US20200383954A1 (es)
EP (1) EP3678659B1 (es)
JP (2) JP2020532555A (es)
KR (1) KR20200047655A (es)
CN (1) CN111093652A (es)
AU (1) AU2018328131B2 (es)
BR (1) BR112020004429A2 (es)
CA (1) CA3074732A1 (es)
IL (1) IL272847A (es)
MA (1) MA50080A (es)
MX (2) MX2020002485A (es)
NZ (1) NZ762056A (es)
SG (1) SG11202001749SA (es)
UA (1) UA126688C2 (es)
WO (1) WO2019050923A1 (es)
ZA (1) ZA202001258B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3145528A1 (en) * 2019-06-28 2020-12-30 The Trustees Of The University Of Pennsylvania Intranasal dantrolene administration for treatment of alzheimer's disease
MX2024005302A (es) * 2021-11-05 2024-05-17 Quorum Innovations Llc Materiales y metodos para prevenir o reducir la toxicidad a los organofosfatos y otros materiales toxicos.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7758890B2 (en) * 2001-06-23 2010-07-20 Lyotropic Therapeutics, Inc. Treatment using dantrolene
ES2862337T3 (es) * 2003-03-04 2021-10-07 Lyotropic Therapeutics Inc Composiciones de dantroleno
US20130071394A1 (en) * 2011-09-16 2013-03-21 John K. Troyer Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use
JP2016501876A (ja) * 2012-11-30 2016-01-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ステロイドの抗痙攣活性

Also Published As

Publication number Publication date
JP2020532555A (ja) 2020-11-12
BR112020004429A2 (pt) 2020-10-20
NZ762056A (en) 2025-10-31
KR20200047655A (ko) 2020-05-07
RU2020112318A3 (es) 2021-10-26
AU2018328131A1 (en) 2020-03-12
ZA202001258B (en) 2023-10-25
SG11202001749SA (en) 2020-03-30
WO2019050923A1 (en) 2019-03-14
AU2018328131B2 (en) 2024-04-18
JP2023055802A (ja) 2023-04-18
US20200383954A1 (en) 2020-12-10
MX2023012415A (es) 2023-11-01
US20220087980A1 (en) 2022-03-24
UA126688C2 (uk) 2023-01-11
IL272847A (en) 2020-04-30
RU2020112318A (ru) 2021-10-06
MA50080A (fr) 2020-07-15
EP3678659B1 (en) 2025-12-17
EP3678659A1 (en) 2020-07-15
CN111093652A (zh) 2020-05-01
CA3074732A1 (en) 2019-03-14

Similar Documents

Publication Publication Date Title
MX2024010140A (es) Nuevos metodos.
MX2023001527A (es) Compuestos con actividad inductora de ferroptosis y metodos de uso de estos.
EA201790195A1 (ru) Способы лечения рака с применением ингибиторов tigit и противораковых агентов
CL2019000935A1 (es) Composición farmacéutica, métodos para tratamiento y usos de la misma.
MX2017015226A (es) Compuestos alqueno tetrasustituidos y su uso.
CL2019002574A1 (es) Moduladores de la expresión de pcsk9.
CL2018002807A1 (es) Métodos de tratamiento de cánceres pediátricos.
AR112102A1 (es) Tinostamustina para utilizar en el tratamiento de cáncer de ovario
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
MX387658B (es) Métodos para tratar y/o prevenir queratosis actínica.
AR112144A1 (es) Compuestos para el tratamiento del sarcoma
PE20191407A1 (es) Uso de gaboxadol en el tratamiento de tinnitus
AR110404A1 (es) MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES FIBRÓTICAS UTILIZANDO EL INTERFERÓN-l
JOP20190056B1 (ar) مركبات للاستخدام في علاج القصور الكلوي الحاد
MX388461B (es) Acetil-leucina o una sal farmacéuticamente aceptable de la misma para mejorar la movilidad y función cognitiva.
EA201892297A1 (ru) Способы лечения холестатических и фибротических заболеваний
CL2019002325A1 (es) Combinaciones farmacéuticas para tratar cáncer.
EA202090266A1 (ru) Ингибиторы mpo для применения в медицине
MX2020002485A (es) Metodos de uso del dantroleno para tratar la exposicion a agente nervioso.
MX2018002298A (es) Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos.
BR112019000706A2 (pt) agente de estímulo do receptor 1b de 5-hidroxitriptamina para reparo de pele e/ou cabelo
CL2022000790A1 (es) Método para tratar vih con cabotegravir y rilpivirina
ZA202103788B (en) Use of dantrolene and dantrolene prodrugs to treat radiation exposure
CL2020000586A1 (es) Moduladores de la expresión de enac.
MX2025002392A (es) Formulaciones de dantroleno y metodos de uso de dichas formulaciones